Patients who have been diagnosed with chronic myeloid leukemia (CML) have been seen to have long-term survival benefits owing to tyrosine kinase inhibitors (TKIs). Regardless of that, long-term TKI-related vascular adverse events (VAEs) have raised a great deal of concern. Analyzing the cases of VAEs in Taiwanese patients who are diagnosed with CML and treated using various TKIs (dasatinib, imatinib, and nilotinib) alongside probable factors of danger was the main aim of the study.
By utilizing the Taiwan Cancer Registry Database and National Health Insurance Research Database, the specialists conducted a backdated cohort review. The researchers recognized adult patients suffering from CML within the time frame from 2008 to 2016 and classified them into three different categories on the basis of their first-line TKI treatment (dasatinib, imatinib, and nilotinib). In order to control for possible confounders, the researchers executed a propensity score matching. Estimation of the hazard ratio (HR) of VAEs in the various TKI groups was done by utilizing Cox regressions.
The study comprised 1,111 patients diagnosed with CML altogether. With an HR of 3.13 (95% CI, 1.30–7.51), the risk of VAEs in patients who used nilotinib was found to be considerably greater than those who used imatinib; with an HR of 1.71 (95% CI, 0.71–4.26), an insignificant pattern for developing VAEs was found in users of dasatinib. Older age, nilotinib usage, and history of cerebrovascular illnesses were some of the danger factors recognized in the multivariable logistic regression analysis. After starting the TKI therapy, the yearly case rate of VAEs was found to be greater in the first year itself.
Link:theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13944
